Cargando…

Non-Native Conformational Isomers of the Catalytic Domain of PCSK9 Induce an Immune Response, Reduce Lipids and Increase LDL Receptor Levels

PCSK9 (Proprotein convertase subtilisin/kexin type 9) increases plasma cholesterol levels by promoting LDL receptor degradation. Current antibody inhibitors block the interaction between PCSK9 and LDL receptors, significantly decrease plasma cholesterol levels, and provide beneficial clinical outcom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Chuantao, Nischal, Hersharan, Sun, Hua, Li, Li, Cao, Ying, Wei, Peng, Chang, Jui-Yoa, Teng, Ba-Bie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855862/ https://www.ncbi.nlm.nih.gov/pubmed/29495280 http://dx.doi.org/10.3390/ijms19020640

Ejemplares similares

Long-term Expression of Apolipoprotein B mRNA-specific Hammerhead Ribozyme via scAAV8.2 Vector Inhibits Atherosclerosis in Mice
por: Nischal, Hersharan, et al.
Publicado: (2013)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
por: Gustafsen, Camilla, et al.
Publicado: (2017)

PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
por: Sun, Hua, et al.
Publicado: (2018)

Pathogenic gain-of-function mutations in the prodomain and C-terminal domain of PCSK9 inhibit LDL binding
por: Sarkar, Samantha K., et al.
Publicado: (2022)

LDL lowering effect of PCSK9 inhibition is reduced in women
por: Myasoedova, Veronika A, et al.
Publicado: (2023)

A Critical Role of PCSK9 in Mediating IL-17-Producing T Cell Responses in Hyperlipidemia
por: Kim, Young Uk, et al.
Publicado: (2019)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
por: Holla, Øystein L, et al.
Publicado: (2007)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
por: Nguyen, My-Anh, et al.
Publicado: (2014)

Back to Basics: PCSK9 as a New Target for the LDL Receptor
por: Corral, Pablo
Publicado: (2014)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

γGT and PCSK9 variants in subjects with hyper-LDL-cholesterolemia
por: Hamasaki, Masato, et al.
Publicado: (2022)

Acaudina molpadioides mediates lipid uptake by suppressing PCSK9 transcription and increasing LDL receptor in human liver cells
por: Jack, Allicia, et al.
Publicado: (2021)

The prenucleosome, a stable conformational isomer of the nucleosome
por: Fei, Jia, et al.
Publicado: (2015)

LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: a focus on white adipose tissue
por: Faraj, May
Publicado: (2020)

CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
por: Kjellmo, Christian Abendstein, et al.
Publicado: (2018)

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
por: Konrad, Robert J, et al.
Publicado: (2011)

Insight into the Formation of Cocrystal and Salt of Tenoxicam from the Isomer and Conformation
por: Xie, Yifei, et al.
Publicado: (2022)

Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis
por: Li, Jiao, et al.
Publicado: (2017)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
por: Schmidt, Amand F., et al.
Publicado: (2019)

Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor
por: Duellman, Sarah J., et al.
Publicado: (2017)

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
por: Rothgangl, Tanja, et al.
Publicado: (2021)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Silencing YY1 Alleviates Ox-LDL-Induced Inflammation and Lipid Accumulation in Macrophages through Regulation of PCSK9/ LDLR Signaling
por: Qian, Zhengyao, et al.
Publicado: (2022)

Dyslipidemia in rat fed with high-fat diet is not associated with PCSK9-LDL-receptor pathway but ageing
por: Jia, Yan-Jun, et al.
Publicado: (2013)

The LDL Receptor Clustering Motif Interacts with the Clathrin Terminal Domain in a Reverse Turn Conformation
por: Kibbey, Richard G., et al.
Publicado: (1998)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C
por: Li, Sha, et al.
Publicado: (2016)

Platelet-Derived PCSK9 Is Associated with LDL Metabolism and Modulates Atherothrombotic Mechanisms in Coronary Artery Disease
por: Petersen-Uribe, Álvaro, et al.
Publicado: (2021)

In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor
por: Min, Dong-Kook, et al.
Publicado: (2015)

Charge, Color, and Conformation: Spectroscopy on Isomer-Selected Peptide Ions
por: Choi, Chang Min, et al.
Publicado: (2016)

Conformational Analysis of Geometric Isomers of Pitavastatin Together with Their Lactonized Analogues
por: Makuc, Damjan, et al.
Publicado: (2013)

Marked Difference in the Conformational Transition of DNA Caused by Propanol Isomer
por: Ma, Yue, et al.
Publicado: (2020)

Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation
por: Seidah, Nabil G., et al.
Publicado: (2012)

Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering
por: Bandyopadhyay, Dhrubajyoti, et al.
Publicado: (2018)

Identification of amino acid residues in the ligand binding repeats of LDL receptor important for PCSK9 binding
por: Deng, Shi-jun, et al.
Publicado: (2019)

Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity
por: Deshycka, Rhogerry, et al.
Publicado: (2021)

Legacy perfluoro-alkyl substances impair LDL-cholesterol uptake independently from PCSK9-function
por: Sabovic, Iva, et al.
Publicado: (2023)

PCSK9 targets important for lipid metabolism
por: Schulz, Rainer, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_flrbabalhtn83nrmmnrieb04k5